
Eli Lilly (LLY) Stock Forecast & Price Target
Eli Lilly (LLY) Analyst Ratings
Bulls say
Eli Lilly reported a robust performance in the second quarter of 2025, exceeding expectations in both revenue and earnings, while also raising its full-year guidance, signaling strong operational momentum. Notably, the growth of Mounjaro sales outside the United States accelerated by 60% quarter-over-quarter, driven by successful market entries in Brazil, Mexico, and India. Additionally, the introduction of orforglipron presents a promising opportunity to expand the GLP-1 market with a convenient oral formulation, enhancing the company's product portfolio in the cardiometabolic sector.
Bears say
Eli Lilly faces significant downside risks that contribute to a negative outlook on its stock, particularly regarding pressure from pricing and rebates in an increasingly competitive market. The prescription trajectory for its drug tirzepatide is falling short of expectations, coupled with concerns over its failure to demonstrate cardiac outcome benefits in non-diabetic obese patients. Additionally, the company has reported a negative impact from Zepbound prescriptions, which is anticipated to hinder volumetric growth in the upcoming quarter.
This aggregate rating is based on analysts' research of Eli Lilly and is not a guaranteed prediction by Public.com or investment advice.
Eli Lilly (LLY) Analyst Forecast & Price Prediction
Start investing in Eli Lilly (LLY)
Order type
Buy in
Order amount
Est. shares
0 shares